Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.52 +0.44 (+0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,048,949
Open 48.12
Bid (Size) 45.98 (1)
Ask (Size) 49.95 (2)
Prev. Close 48.08
Today's Range 48.05 - 48.96
52wk Range 42.63 - 55.72
Shares Outstanding 1,250,690,553
Dividend Yield 3.92%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Will Novavax Be in 1 Year?
We will know a lot more about the vaccine maker's long-term prospects in 12 months. 
Via The Motley Fool
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-2.96%
-2.96%
1 Month
+2.00%
+2.00%
3 Month
+0.48%
+0.48%
6 Month
-2.43%
-2.43%
1 Year
-8.44%
-8.44%

More News

Read More
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Via InvestorPlace
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Via Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Is It Too Late to Buy Novavax Stock?
Via The Motley Fool
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Via Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Via The Motley Fool
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Via Investor's Business Daily
Exposures COVID-19
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
Via InvestorPlace
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
Via InvestorPlace
Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients
Via Benzinga
3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth
Via InvestorPlace
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet
Via InvestorPlace
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Vaccine Stocks Rallied This Week
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.